1. Home
  2. DBVT vs BLNK Comparison

DBVT vs BLNK Comparison

Compare DBVT & BLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • BLNK
  • Stock Information
  • Founded
  • DBVT 2002
  • BLNK 2009
  • Country
  • DBVT France
  • BLNK United States
  • Employees
  • DBVT N/A
  • BLNK N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • BLNK Industrial Specialties
  • Sector
  • DBVT Health Care
  • BLNK Consumer Discretionary
  • Exchange
  • DBVT Nasdaq
  • BLNK Nasdaq
  • Market Cap
  • DBVT 102.0M
  • BLNK 105.2M
  • IPO Year
  • DBVT N/A
  • BLNK N/A
  • Fundamental
  • Price
  • DBVT $6.46
  • BLNK $0.94
  • Analyst Decision
  • DBVT Strong Buy
  • BLNK Buy
  • Analyst Count
  • DBVT 2
  • BLNK 8
  • Target Price
  • DBVT $22.50
  • BLNK $3.31
  • AVG Volume (30 Days)
  • DBVT 1.1M
  • BLNK 3.5M
  • Earning Date
  • DBVT 05-06-2025
  • BLNK 03-13-2025
  • Dividend Yield
  • DBVT N/A
  • BLNK N/A
  • EPS Growth
  • DBVT N/A
  • BLNK N/A
  • EPS
  • DBVT N/A
  • BLNK N/A
  • Revenue
  • DBVT $4,200,000.00
  • BLNK $126,197,000.00
  • Revenue This Year
  • DBVT $1,679.52
  • BLNK $25.90
  • Revenue Next Year
  • DBVT $535.67
  • BLNK $35.81
  • P/E Ratio
  • DBVT N/A
  • BLNK N/A
  • Revenue Growth
  • DBVT N/A
  • BLNK N/A
  • 52 Week Low
  • DBVT $0.44
  • BLNK $0.86
  • 52 Week High
  • DBVT $7.28
  • BLNK $3.75
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 65.77
  • BLNK 42.86
  • Support Level
  • DBVT $3.91
  • BLNK $0.86
  • Resistance Level
  • DBVT $7.28
  • BLNK $1.05
  • Average True Range (ATR)
  • DBVT 0.60
  • BLNK 0.07
  • MACD
  • DBVT 0.20
  • BLNK 0.00
  • Stochastic Oscillator
  • DBVT 75.67
  • BLNK 36.08

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.

Share on Social Networks: